0401 (0401) Fair Value & Analysis

Healthcare · Market cap HK$142M

0 0401 0401 · HK

PriceHK$0.1260

Fair ValueHK$0.0600

Upside-52.4%

Quality64/100

Evidence: Medium Range HK$0.0500 – HK$0.0700

Fair value as of: Jul 1, 2026

From 11 valuation models · updated today

Share price −33.7% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$0.0452 – HK$0.2020 · fair‑value band HK$0.0500 – HK$0.0700 · the HK$0.1260 price screens above the HK$0.0600 fair value. As of Jul 1, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

0401 (0401) currently trades at HK$0.1260, while our model-based Fair Value estimate is HK$0.0600 — implying the stock looks roughly 52.4% overvalued today. We read business quality at 64/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

Over the trailing twelve months, 0401 generated revenue of HK$164M at a net margin of -5.2%. Revenue grew 2.4% year over year. It earns a return on equity of -11.9%. The balance sheet holds a net cash position of HK$12.4M. Fundamentals as of Jul 1, 2026

Key figures & financial health

Revenue (TTM) HK$164M

Revenue growth (YoY) +2.4%

Net margin -5.2%

Return on equity -11.9%

Free cash flow HK$9.9M FY2025

Operating margin 0.9%

More key figures

EPS (TTM) HK$-0.0100

Net cash HK$12.4M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 1, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

0401 reported revenue of HK$162M in FY2025 versus HK$114M in FY2021, a compound +9.1%/yr. Reported net income was −HK$6.6M in FY2025.

Revenue +9.1%/yr

FY21 HK$114M

FY22 HK$155M

FY23 HK$174M

FY24 HK$181M

FY25 HK$162M

Net income

FY21 −HK$4.5M

FY22 −HK$51.0M

FY23 HK$1.8M

FY24 −HK$40.0M

FY25 −HK$6.6M

Is 0401 fairly valued? → Check now

Similar stocks

6 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Jul 1, 2026).

Stock	Price	Fair Value	vs Fair Value
McKesson Corporation M1CK34	R$999.49	R$1,236	+24%
Cencora, Inc C1CO34	R$707.04	R$79.88	-89%
Cardinal Health, Inc CAH	$201.74	$92.07	-54%
Sigma Healthcare Limited SIGGF	$2.35	$0.6300	-73%
Sitka Gold Corp SIG	A$2.92	A$1.20	-59%
Shanghai Pharmaceuticals Holding 601607	¥15.96	¥45.15	+183%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 0401 (0401) undervalued?

As of Jul 1, 2026, our model estimates a fair value of HK$0.0600 versus a price of HK$0.1260 — about −52% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 0401?

Our model-based fair value for 0401 is HK$0.0600 (as of Jul 1, 2026), built from audited fundamentals. The current price is HK$0.1260.

What is the quality score of 0401?

0401 has a Quality Score of 64/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 0401 (0401)?

0401 reported trailing-twelve-month revenue of about HK$164M (latest available figure, as of Jul 1, 2026).

What is the net profit margin of 0401?

The net profit margin of 0401 is about -5.2%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.